The Human Pancreas Analysis Program consists of two interlocking, collaborative projects at three institutions that seek to provide comprehensive molecular profiling in unprecedented detail of the pancreatic islet at various stages of type 1 diabetes (T1D) pathogenesis- pre-diabetic (positive islet autoantibodies), recent onset, and T1D of durations less than 10 years.

In the past decade, there have been dramatic advances in our ability to phenotype and molecularly profile human cells and tissues. HIRN-HPPAP will develop and apply these new technologies to study cells and tissues relevant to the beta cell loss in T1D with unprecedented resolution, including at the genomic, epigenomic, protein, and functional levels. Here we will employ state-of-the-art technologies to determine all aspects of pancreatic islet cell and immune cell biology as it pertains to the pathogenesis of type 1 diabetes. We will profile both the endocrine and immune systems with multiple modalities, and make the vast data accumulated available through the highly accessible PANC-DB, which will be developed through the project. These extensive and high quality datasets will be made available to the HIRN and the diabetes research community at-large for further discovery.

HPAP Projects:

•  Penn Integrated Human Pancreas Procurement and Analysis Program
• Integrated Program for Human Pancreas Procurement and Analysis